Iovance Q1 Revenue at $71.43M, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy IOVA?
Reports Q1 revenue $71.43M, consensus $75.66M. Frederick Vogt, interim President and Chief Executive Officer of Iovance, stated, "We are accelerating the adoption and commercial expansion for Amtagvi after record high demand. Iovance is well positioned through 2026 for long-term revenue growth, while advancing multiple ongoing and new clinical trials, including our registrational trial in advanced sarcomas now underway and encouraging initial data reported today for lifileucel in metastatic serous endometrial cancer. Internal manufacturing efficiencies, operational improvements, and cost reductions will benefit gross margin and propel future profitability, sustainable growth, and long-term value for patients and shareholders."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IOVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IOVA
Wall Street analysts forecast IOVA stock price to rise
8 Analyst Rating
6 Buy
1 Hold
1 Sell
Moderate Buy
Current: 3.550
Low
1.50
Averages
9.50
High
17.00
Current: 3.550
Low
1.50
Averages
9.50
High
17.00
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Iovance Reports Wider Than Expected Q1 Loss Amid Approval Delays
- Q1 Financial Results: Iovance reported a Q1 loss of $0.19 per share, exceeding the expected loss of $0.15, while revenue increased by 45% to $71.4 million, which fell short of Wall Street's estimate of $75.6 million, indicating challenges in balancing revenue growth with profitability.
- Q2 Revenue Forecast: The company forecasts total product revenue for Q2 between $86 million and $88 million, reflecting management's cautious outlook on future sales, particularly amid ongoing regulatory approval delays.
- Withdrawal of Marketing Application: Iovance withdrew its marketing authorization application for Amtagvi in the UK due to procedural issues, which may prolong its entry into the European market and heighten investor concerns regarding the company's future growth prospects.
- Investor Sentiment Shift: Despite Iovance's stock gaining 23% so far in 2026, retail sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', reflecting a divergence in market confidence regarding the company's product potential and management capabilities.
See More
Iovance Biotherapeutics Misses Q1 Expectations, Shares Drop
- Disappointing Performance: Iovance Biotherapeutics reported Q1 2026 revenue of $71 million, missing market expectations by $4.7 million despite a year-over-year growth of approximately 45%, leading to a nearly 10% drop in premarket shares as analysts expressed concerns over the shortfall.
- Cost Control Success: The company successfully reduced its R&D and SG&A expenses by about 18% and 11%, respectively, to $62.5 million and $38.9 million, indicating effective cost management; however, the net loss per share of $0.19 still missed forecasts by $0.04, although it represented a 47% year-over-year improvement.
- Optimistic Outlook: Iovance projects full-year revenue for 2026 to be between $350 million and $370 million, aligning with the consensus estimate of $359.7 million, while the Q2 revenue forecast of $86 million to $88 million exceeds the analysts' projection of $84.3 million, primarily driven by U.S. sales of Amtagvi.
- Executive Transition: Chief Medical Officer Friedrich Graf Finckenstein, who played a pivotal role in the development of Amtagvi and other therapeutic candidates, is set to retire in June 2026, with the company indicating that a successor will be announced soon, which could impact future R&D strategies.
See More
Iovance Biotherapeutics Q1 Earnings Analysis
- Earnings Performance: Iovance Biotherapeutics reported a Q1 GAAP EPS of -$0.19, missing expectations by $0.04, with revenue of $71 million reflecting a 44% year-over-year increase but still falling short of projections, indicating challenges during maintenance periods.
- Gross Margin Impact: The gross margin stood at 41%, impacted by one-time costs associated with annual maintenance and internal facility expansion; however, operational efficiencies led to a 12% decrease in R&D expenses, marking a third consecutive quarter of improvement.
- Future Guidance: The company anticipates Q2 2026 product revenue between $86 million and $88 million, with full-year guidance set at $350 million to $370 million, highlighting strong demand and growth potential for Amtagvi.
- Growing Market Demand: Demand for Amtagvi is accelerating, driven by real-world data showing a 52% objective response rate in patients with two or fewer prior lines of therapy, establishing a solid foundation for the company's future growth.
See More
Iovance Biotherapeutics Set to Announce Q1 Earnings on May 7
- Earnings Announcement: Iovance Biotherapeutics is set to release its Q1 2023 earnings report on May 7 before market open, with consensus EPS estimates at -$0.15 and revenue projected at $75.66 million, reflecting a robust year-over-year growth of 53.4%.
- Earnings Estimate Changes: Over the last three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates have experienced no upward revisions but two downward adjustments, indicating mixed market sentiment regarding the company's short-term profitability.
- Competitive Landscape: Despite facing competitive pressures, Iovance is viewed as well-positioned for multi-year growth, particularly with new indications that could enhance its market share and product adoption.
- Future Outlook: The company aims for a 30% revenue growth by Q4 2025 while expanding the adoption of Amtagvi and its pipeline, demonstrating a proactive strategic approach towards profitability and market expansion.
See More
Iovance Biotherapeutics Stock Performance Analysis
- Stock Performance: Iovance Biotherapeutics has seen a 34% increase in stock price this year, yet it has lost nearly 90% of its value over the past five years, highlighting the contrast between short-term gains and long-term challenges.
- Revenue Growth: The company reported total revenue of $263.5 million in 2025, reflecting a nearly 61% increase from 2024, primarily driven by the success of its flagship product, Amtagvi, in melanoma treatment.
- Market Opportunity: Amtagvi presents a vast global opportunity in the melanoma market, with potential annual sales exceeding $1 billion in the coming years, particularly fueled by rapid growth in the U.S. market.
- Clinical Trial Risks: Iovance faces significant risks related to the clinical trial outcomes for lifileucel and its ability to expand market access; failure to meet critical milestones could lead to a substantial decline in stock price.
See More
IOVA Benefits from Rival Drug Rejection, Analysts Bullish
- FDA Drug Rejection Impact: The FDA's rejection of Replimune's RP1 due to insufficient data is viewed positively for Iovance's Amtagvi, enhancing its competitive position in the near term and potentially increasing market share.
- Sales Growth Expectations: Iovance's Amtagvi is projected to generate approximately $220 million in revenue for 2025, with analysts highlighting that sales acceleration and margin expansion will be central to the company's future growth.
- Market Reaction Analysis: Despite the FDA rejection being seen as a positive development, IOVA's stock fell 8%, surprising retail investors and indicating the complexity of market sentiment surrounding the stock.
- Analyst Ratings Optimistic: Among 11 analysts, 8 have rated IOVA as a 'Buy', with an average 12-month price target of $9, representing a potential upside of about 144%, reflecting strong confidence in its future performance.
See More
Iovance Reports Wider Than Expected Q1 Loss Amid Approval Delays
- Q1 Financial Results: Iovance reported a Q1 loss of $0.19 per share, exceeding the expected loss of $0.15, while revenue increased by 45% to $71.4 million, which fell short of Wall Street's estimate of $75.6 million, indicating challenges in balancing revenue growth with profitability.
- Q2 Revenue Forecast: The company forecasts total product revenue for Q2 between $86 million and $88 million, reflecting management's cautious outlook on future sales, particularly amid ongoing regulatory approval delays.
- Withdrawal of Marketing Application: Iovance withdrew its marketing authorization application for Amtagvi in the UK due to procedural issues, which may prolong its entry into the European market and heighten investor concerns regarding the company's future growth prospects.
- Investor Sentiment Shift: Despite Iovance's stock gaining 23% so far in 2026, retail sentiment on Stocktwits shifted from 'bullish' to 'extremely bullish', reflecting a divergence in market confidence regarding the company's product potential and management capabilities.
See More
Iovance Biotherapeutics Misses Q1 Expectations, Shares Drop
- Disappointing Performance: Iovance Biotherapeutics reported Q1 2026 revenue of $71 million, missing market expectations by $4.7 million despite a year-over-year growth of approximately 45%, leading to a nearly 10% drop in premarket shares as analysts expressed concerns over the shortfall.
- Cost Control Success: The company successfully reduced its R&D and SG&A expenses by about 18% and 11%, respectively, to $62.5 million and $38.9 million, indicating effective cost management; however, the net loss per share of $0.19 still missed forecasts by $0.04, although it represented a 47% year-over-year improvement.
- Optimistic Outlook: Iovance projects full-year revenue for 2026 to be between $350 million and $370 million, aligning with the consensus estimate of $359.7 million, while the Q2 revenue forecast of $86 million to $88 million exceeds the analysts' projection of $84.3 million, primarily driven by U.S. sales of Amtagvi.
- Executive Transition: Chief Medical Officer Friedrich Graf Finckenstein, who played a pivotal role in the development of Amtagvi and other therapeutic candidates, is set to retire in June 2026, with the company indicating that a successor will be announced soon, which could impact future R&D strategies.
See More
Iovance Biotherapeutics Q1 Earnings Analysis
- Earnings Performance: Iovance Biotherapeutics reported a Q1 GAAP EPS of -$0.19, missing expectations by $0.04, with revenue of $71 million reflecting a 44% year-over-year increase but still falling short of projections, indicating challenges during maintenance periods.
- Gross Margin Impact: The gross margin stood at 41%, impacted by one-time costs associated with annual maintenance and internal facility expansion; however, operational efficiencies led to a 12% decrease in R&D expenses, marking a third consecutive quarter of improvement.
- Future Guidance: The company anticipates Q2 2026 product revenue between $86 million and $88 million, with full-year guidance set at $350 million to $370 million, highlighting strong demand and growth potential for Amtagvi.
- Growing Market Demand: Demand for Amtagvi is accelerating, driven by real-world data showing a 52% objective response rate in patients with two or fewer prior lines of therapy, establishing a solid foundation for the company's future growth.
See More
Iovance Biotherapeutics Set to Announce Q1 Earnings on May 7
- Earnings Announcement: Iovance Biotherapeutics is set to release its Q1 2023 earnings report on May 7 before market open, with consensus EPS estimates at -$0.15 and revenue projected at $75.66 million, reflecting a robust year-over-year growth of 53.4%.
- Earnings Estimate Changes: Over the last three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates have experienced no upward revisions but two downward adjustments, indicating mixed market sentiment regarding the company's short-term profitability.
- Competitive Landscape: Despite facing competitive pressures, Iovance is viewed as well-positioned for multi-year growth, particularly with new indications that could enhance its market share and product adoption.
- Future Outlook: The company aims for a 30% revenue growth by Q4 2025 while expanding the adoption of Amtagvi and its pipeline, demonstrating a proactive strategic approach towards profitability and market expansion.
See More
Iovance Biotherapeutics Stock Performance Analysis
- Stock Performance: Iovance Biotherapeutics has seen a 34% increase in stock price this year, yet it has lost nearly 90% of its value over the past five years, highlighting the contrast between short-term gains and long-term challenges.
- Revenue Growth: The company reported total revenue of $263.5 million in 2025, reflecting a nearly 61% increase from 2024, primarily driven by the success of its flagship product, Amtagvi, in melanoma treatment.
- Market Opportunity: Amtagvi presents a vast global opportunity in the melanoma market, with potential annual sales exceeding $1 billion in the coming years, particularly fueled by rapid growth in the U.S. market.
- Clinical Trial Risks: Iovance faces significant risks related to the clinical trial outcomes for lifileucel and its ability to expand market access; failure to meet critical milestones could lead to a substantial decline in stock price.
See More
IOVA Benefits from Rival Drug Rejection, Analysts Bullish
- FDA Drug Rejection Impact: The FDA's rejection of Replimune's RP1 due to insufficient data is viewed positively for Iovance's Amtagvi, enhancing its competitive position in the near term and potentially increasing market share.
- Sales Growth Expectations: Iovance's Amtagvi is projected to generate approximately $220 million in revenue for 2025, with analysts highlighting that sales acceleration and margin expansion will be central to the company's future growth.
- Market Reaction Analysis: Despite the FDA rejection being seen as a positive development, IOVA's stock fell 8%, surprising retail investors and indicating the complexity of market sentiment surrounding the stock.
- Analyst Ratings Optimistic: Among 11 analysts, 8 have rated IOVA as a 'Buy', with an average 12-month price target of $9, representing a potential upside of about 144%, reflecting strong confidence in its future performance.
See More
